Insider Trading Alert - GNMK, CPSS And BKD Traded By Insiders

Yesterday, Sept. 16, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $4,488,945.00.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 14,245 shares at $9.98 on Sept. 16, 2015. Following this transaction, the SVP, Human Resources owned 118,547 shares meaning that the stake was reduced by 10.73% with the 14,245-share transaction.

The shares most recently traded at $9.90, down $0.08, or 0.8% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 31,970
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 32,523
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 52,294

The average volume for GenMark Diagnostics has been 195,800 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $417.5 million and is part of the health care sector and health services industry. Shares are down 27.48% year-to-date as of the close of trading on Wednesday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings rates GenMark Diagnostics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, unimpressive growth in net income and feeble growth in its earnings per share. Get the full GenMark Diagnostics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Consumer Portfolio Services (CPSS) - FREE Research Report

Washer Greg, who is Director at Consumer Portfolio Services, bought 2,000 shares at $5.31 on Sept. 16, 2015. Following this transaction, the Director owned 282,744 shares meaning that the stake was boosted by 0.71% with the 2,000-share transaction.

The shares most recently traded at $5.52, up $0.21, or 3.8% since the insider transaction. Historical insider transactions for Consumer Portfolio Services go as follows:

  • 4-Week # shares bought: 9,500
  • 4-Week # shares sold: 50,000
  • 12-Week # shares bought: 15,500
  • 12-Week # shares sold: 50,000
  • 24-Week # shares bought: 41,500
  • 24-Week # shares sold: 50,000

The average volume for Consumer Portfolio Services has been 167,400 shares per day over the past 30 days. Consumer Portfolio Services has a market cap of $139.5 million and is part of the financial sector and financial services industry. Shares are down 25.27% year-to-date as of the close of trading on Wednesday.

Consumer Portfolio Services, Inc. operates as a specialty finance company in the United States. The company has a P/E ratio of 5.2. Currently, there is 1 analyst who rates Consumer Portfolio Services a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPSS - FREE

TheStreet Quant Ratings rates Consumer Portfolio Services as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, poor profit margins and a generally disappointing performance in the stock itself. Get the full Consumer Portfolio Services Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Brookdale Senior Living (BKD) - FREE Research Report

Kaestner H Todd, who is Executive Vice President at Brookdale Senior Living, sold 253 shares at $26.58 on Sept. 16, 2015. Following this transaction, the Executive Vice President owned 92,301 shares meaning that the stake was reduced by 0.27% with the 253-share transaction.

Hicks George T, who is Executive Vice President at Brookdale Senior Living, sold 144 shares at $26.58 on Sept. 16, 2015. Following this transaction, the Executive Vice President owned 148,639 shares meaning that the stake was reduced by 0.1% with the 144-share transaction.

Ferge Kristin A, who is EVP & Chief Accounting Officer at Brookdale Senior Living, sold 846 shares at $26.58 on Sept. 16, 2015. Following this transaction, the EVP & Chief Accounting Officer owned 106,859 shares meaning that the stake was reduced by 0.79% with the 846-share transaction.

The shares most recently traded at $26.74, up $0.16, or 0.58% since the insider transaction. Historical insider transactions for Brookdale Senior Living go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 7,500
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 7,500
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 203,034

The average volume for Brookdale Senior Living has been 2.9 million shares per day over the past 30 days. Brookdale Senior Living has a market cap of $5.0 billion and is part of the health care sector and health services industry. Shares are down 26.7% year-to-date as of the close of trading on Friday.

Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Continuing Care Retirement Communities (CCRCs)-Rental, Brookdale Ancillary Services, and Management Services. Currently, there are 4 analysts who rate Brookdale Senior Living a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BKD - FREE

TheStreet Quant Ratings rates Brookdale Senior Living as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Brookdale Senior Living Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

5 Things Investors Should Read Before Coming Earnings Season Blowout

5 Things Investors Should Read Before Coming Earnings Season Blowout

In Trump Era, Managing JPMorgan Is As Unpredictable As a Midnight Tweet

In Trump Era, Managing JPMorgan Is As Unpredictable As a Midnight Tweet

Video: Don't Underestimate China's Strength in a Trade War

Video: Don't Underestimate China's Strength in a Trade War

Master Limited Partnerships: A Badly Missed Investment Opportunity?

Master Limited Partnerships: A Badly Missed Investment Opportunity?

America's Massive Truck Driver Shortage May Triple by 2026: Experts

America's Massive Truck Driver Shortage May Triple by 2026: Experts